Search tips
Search criteria 


Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
J Psychiatry Neurosci. 1999 November; 24(5): 453–455.
PMCID: PMC1189059

The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.


OBJECTIVE: To investigate the effects of 12 weeks of clozapine treatment on levels of cholesterol and related lipids in patients with schizophrenia. DESIGN: Prospective study. SETTING: University department associated with a teaching hospital. PARTICIPANTS: Eight patients (6 women and 2 men) with a clinical diagnosis of schizophrenia consistent with DSM-IV criteria. The patients were classified as treatment-resistant and had not responded to treatment with at least 2 conventional antipsychotics. INTERVENTIONS: Current antipsychotic medications were tapered and treatment with clozapine was initiated. OUTCOME MEASURES: Cholesterol and serum lipid levels, as well as Brief Psychiatric Rating Scale (BPRS) scores were measured before and after 12 weeks of treatment with clozapine. RESULTS: Clozapine treatment significantly improved the BPRS scores but did not significantly alter serum lipid levels, except triglyceride levels, which increased. CONCLUSION: The previously reported lower levels of cholesterol in treatment-resistant patients with schizophrenia cannot be attributed to the effects of clozapine administration. Further research is required to support and clarify the effects of antipsychotic drugs on lipid levels.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (623K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hawthon K, Cowen P, Owens D, Bond A, Elliott M. Low serum cholesterol and suicide. Br J Psychiatry. 1993 Jun;162:818–825. [PubMed]
  • Boston PF, Dursun SM, Zafar R, Reveley MA. Serum cholesterol and treatment-resistance in schizophrenia. Biol Psychiatry. 1996 Sep 15;40(6):542–543. [PubMed]
  • Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996 Sep 1;53(17):2079–2081. [PubMed]
  • Muldoon MF, Kaplan JR, Manuck SB, Mann JJ. Effects of a low-fat diet on brain serotonergic responsivity in cynomolgus monkeys. Biol Psychiatry. 1992 Apr 1;31(7):739–742. [PubMed]
  • Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL. Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 1993 Sep;150(9):1337–1342. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association